Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sciformix to Reveal Strategic Model for Talent Acquisition at the DIA 50th Annual Meeting

Published: Thursday, May 22, 2014
Last Updated: Thursday, May 22, 2014
Bookmark and Share
New career strategy aims to address talent acquisition and retention requirements for capacity expansion.

Sciformix Corporation will unveil a new strategic model for talent acquisition and retention at the DIA 50th Annual Meeting, San Diego, California, which will take place 15th to 19th June.

The new model will demonstrate the ability to cater for the increasing demand for talent in the CRO industry, enabling capacity expansion without compromising productivity and the quality of deliverables.

The talent pool for the CRO industry is currently at a critical level, with an ever increasing demand for trained candidates, especially in highly skilled roles.

The demand-supply skew has stretched the limit of current hiring practices aimed at external sourcing of experienced talent. The problem is more acute for companies such as Sciformix, that work in areas of high science and high domain where lateral hiring isn’t the solution.

Sciformix has implemented a novel model of systematized training by developing a structured curriculum both for entry level and experienced candidates. By focusing on in-house professional development, the program will provide not only a stream of trained resources, but also make experienced resources productive on complex assignments they don’t have prior experience on.

In a presentation, to take place at DIA 50th Annual Meeting on 19th June, Dr. Samyuktha Ajay, Practice Head for Clinical Research and Post-Approval Support Services at Sciformix, will outline this new strategic initiative and share the experience and benefits of the program.

Dr. Ajay said: “According to various market research reports, the CRO industry is expected to grow to $32.7 billion by next year, to over $65.0 billion by 2021, and has created an increased demand for a rich talent pool of medical, paramedical and science graduates to supply capacity expansion. CROs and their service providers are creating new positions and promoting internal employees which is driving significant movement amongst companies and, thus, creating further resource crunch. Despite candidates being readily available, finding the right match requires the adoption of a multi-dimensional strategy. Through sharing our extensive experience of in-house training at all levels, we aim to project a program which offers a structured career path and excellent retention strategy.”

The DIA 2014 50th annual meeting is the largest multidisciplinary event that brings together the community of life sciences professionals at all levels and across all disciplines involved in the discovery, development and life cycle management of medical products and therapies to patients.

DIA will provide a platform to raise the level of discussion to facilitate innovation that will change the future of health care and it will provide coverage of the full development and life cycle management of process for health care products.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sciformix Corporation CSO Honoured in PharmaVOICE 100
Dr. Chitra Lele is recognized for pioneering work in service provision across global markets.
Friday, August 01, 2014
Sciformix Awarded Pharmaceutical KPO Entrepreneurial Company of the Year
Company has received this prestigious award from Frost & Sullivan.
Thursday, July 18, 2013
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!